← Russell 3000 cross-section

BIO BIO-RAD LABORATORIES, INC.

Trailing twelve months to 2026-06-30 · as filed 2026-08-04, not restated
Healthcare

Scale

Market cap
$10.4bn
Revenue TTM
$2.6bn
Net income TTM
$222m
Free cash flow
$353m
Composite score
43.0
Sector rank
#691

Valuation

P / E
46.9
EV / EBITDA
EV / sales
3.7
FCF yield
3.38%
Earnings yield vs 10-yr
-2.60pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
8.6%
EBITDA margin
ROE
3.1%
ROIC
0.8%
Revenue growth
1.4%

Insider activity, last 90 days

Net open-market
$0.00m
Buyers
0
Sellers
0

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

Approximately 39% of our 2026 consolidated net sales are derived from the United States and approximately 61% are derived from international locations, with Europe being our largest international region. When the U.S. dollar strengthens, we benefit from lower cost of sales from our own international manufacturing sites, and from lower international operating expenses. Three Months Ended June 30, 2026 Compared to Three Months Ended June 30, 2025 Results of Operations – Sales, Gross Margins and Expenses Percentage sales growth in currency-neutral amounts are calculated by translating prior period sales in each local currency using the current period monthly average foreign exchange rates for t …BIO-RAD LABORATORIES, INC., 10-Q, period ended 2026-06-30, filed 2026-08-04

Read the full passage →